Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.70 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | PTGIR | P43119 | 2/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Am-211 SCHEMBL138450 | 0.90 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| Am-211 SCHEMBL29433664 | 0.90 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL17387644 | 0.88 | PTGDR2 (0.72) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL154679 | 0.87 | PTGDR2 (0.78) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL153719 | 0.86 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL152502 | 0.85 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL138678 | 0.85 | PTGDR2 (0.75) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL139889 | 0.85 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL17387658 | 0.84 | PTGDR2 (0.73) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL137919 | 0.83 | PTGDR2 (0.89) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2521713-A2 | DP2 ANTAGONIST AND USES THEREOF | Panmira Pharmaceuticals, LLC (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011085033-A2 | DP2 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGDR2, PTGES2 | PTGDR2 2/4885TBXA2R 9/4885PTGDR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.